Deinove, the world’s leading specialist in using Deinococcus bacteria for biofuels, green chemistry and antibiotics, has announced that its Deinobiotics project is to receive a total of €1.35 million in grants and loans.
The Deinobiotics project has been accredited by the Eurobiomed cluster as part of the 9th call for proposals by the French government’s competitiveness clusters programme, funded by the Inter-ministerial Fund (FUI). The project consortium comprises Deinove, as the project leader, the Nîmes-based biotech company Nosopharm, a specialist in antibiotic screening, the CPBS (a joint CNRS-University of Montpellier lab for the study of dangerous pathogens) and the Institute for Structural Genomics (CNRS Marseilles).
The funding will be distributed as follows: Deinove will receive €0.7 million in grants and reimbursable loans from OSEO, the French state innovation agency, the Languedoc-Roussillon Regional Council and the European Regional Development Fund (ERDF); the FUI will grant €0.11 million to Nosopharm, €0.2 million for the IGS and €0.34 million to the CPBS.
Deinove will own a worldwide, exclusive licence to all the intellectual property rights generated in the Deinobiotics project. The company intends to commercialise these rights by out-licensing to a pharmaceutical company.
Receive our news bulletin each Tuesday & Thursday and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
